|Home | About | Journals | Submit | Contact Us | Français|
To conduct and report monitoring of vitamin K deficiency bleeding (VKDB) in Great Britain and Ireland following the 1988–90 survey (VKDB‐90).
Two 2‐year surveys conducted during 1993–4 (VKDB‐94) and 2001–02 (VKDB‐02).
Data collected from all consultant paediatricians in Great Britain and Ireland.
All infants presenting with bleeding resulting from vitamin K (VK) deficiency.
Incidence of VKDB, related mortality/morbidity and VK prophylaxis recommended/received, noting predisposing features.
Compared with previous studies, VKDB‐02 found fewer cases of VKDB (RR: 0.27 (95% CI: 0.12 to 0.59), p<0.001) with no deaths, no long‐term morbidity and reduced incidence among those receiving any oral dosing (RR: 0.24 (95% CI: 0.06 to 1.01), p<0.059). Breast‐fed infants accounted for the vast majority of cases. The number receiving no prophylaxis fell consecutively over time: 20 of 27 in VKDB‐90, 10 of 32 in VKDB‐94 and 4 (because of parental refusal) of 7 in VKDB‐02. Seven received one oral dose of VK in VKDB‐90, 16 in VKDB‐94 and none in VKDB‐02. Underlying liver disease was found in six cases in VKDB‐90, 12 in VKDB‐94 and one in VKDB‐02.
In the most recent survey, the incidence of VKDB was about one third that in the two earlier studies. Late onset VKDB remains virtually confined to breast‐fed infants who have received either no VK or just one oral dose. The effectiveness of oral prophylaxis regimens has improved over the last 15 years, but parental refusal of prophylaxis has become more problematic.
At the time of the first prospective survey of vitamin K deficiency bleeding (VKDB) in Great Britain and Ireland (1988–90), some 60% of neonates were offered intramuscular (IM) vitamin K (VK) prophylaxis and 30% an oral regimen.1 Konakion Neonatal (Roche, Basel, Switzerland), containing Cremophor EL as the solubilising agent, was the single available preparation and was licensed only for parenteral use. Of the 27 cases of VKDB, 20 had received no prophylaxis and seven oral VK; 24 were exclusively breast fed; liver disease was identified in seven; in 14 there was a delay (1–14 days) between the first bleeding manifestation and presentation to hospital; 10 had intracranial haemorrhage (ICH), six of them after “warning bleeds” of 1–14 days' duration; and of those with ICH, two died and all others suffered significant sequelae.2
The report emphasised the need for VK prophylaxis for all newborns, repeated doses in breast‐fed infants given oral prophylaxis, early investigation of babies with evidence of cholestasis and emergency investigation of “warning bleeds”.3 To monitor progress, two further 2‐year prospective surveys were conducted by the same methods in the same study area; all three surveys were carried out under the auspices of the British Paediatric Surveillance Unit (BPSU). In this paper the surveys are referred to as VKDB‐90, VKDB‐94 and VKDB‐02; the findings of VKDB‐94 (1993–4) and VKDB‐02 (2001–02) are reported.
Cases of VKDB are conventionally divided into three groups according to age at onset of bleeding: “early” (onset within 24 h of birth), “classical” (onset 1–7 full days after birth) and “late” (onset after 7 days). Although somewhat arbitrary, these groupings are helpful in considering aetiology, mode of presentation and prophylaxis,4 and so are used in this report.
Cases were recruited by means of the well‐described BPSU methodology as in VKDB‐90.2 “Vitamin K deficiency bleeding” was included among the reportable conditions between January 1993–December 1994 and January 2001–December 2002 inclusive. Paediatricians in Great Britain and Ireland were asked to report all possible cases, defined as: “Any infant under 6 months of age with spontaneous bruising/bleeding or ICH associated with prolonged clotting times, not due to an inherited coagulopathy or disseminated intravascular coagulation”. The questionnaires requested details of maternal medication, pregnancy and delivery, birth weight, VK prophylaxis, type of feeding, the site/timing of bleeding, investigations, treatment and outcome. Cases were classified, according to the same criteria used in VKDB‐90, as “confirmed” (appropriate history of bleeding, documented prothrombin time or INR at least twice the control value, platelet count normal or raised, no evidence of infection/disseminated intravascular coagulation), “probable” (appropriate history of bleeding, diagnosis other than VKDB unlikely but lacking full laboratory confirmation), “duplicate” (already notified), “no case” (criteria not met) or “error”.
A report in 19975 compared incidences of late VKDB from the Netherlands, Germany, Australia and Switzerland and related them to different prophylaxis policies. It used case definition criteria, agreed internationally in 1994,5 which were more exclusive than those of the BPSU studies (above) devised by us in 1987 for the first study. For comparison with these data from other countries, the cases of late VKDB reported to the BPSU studies were re‐classified according to these stricter criteria.
Birth statistics were obtained from the appropriate national bodies.
During the two study periods, 93.1% and 92.5% of the BPSU monthly report cards were returned, demonstrating excellent cooperation from paediatricians in the study area.
There were 111 notifications; 103 questionnaires were returned yielding 30 confirmed and two probable cases, 13 duplicates, and 58 “no case” or “error” reports. Both probable cases suffered ICH but had relatively minor prolongation of clotting times; in case 4 excessive birth weight and difficult delivery may have caused the bleeding.
There were 42 notifications; 39 questionnaires were returned yielding seven confirmed and no probable cases, five duplicates and 27 “no case” or “error” reports.
There were 17 boys and 26 were born by normal delivery. Case 31 was born at 32 weeks' gestation and all others were born at term. Median birth weight was 3.4 kg (range 2.2–4.7 kg). Three babies were formula fed (soy formula in two), two had mixed feeds, 25 were solely breast fed, one predominantly so and one was unfed.
All were born at term (gestation 370‐416 weeks) and weighed 2.5–4.0 kg (neither gender nor exact weight were requested, to reduce data risks). One baby was predominantly formula fed (soy) and six solely breast fed.
Ten received no VK prophylaxis, which was due to error in three cases, parental refusal in four (in one the recommendation was for IM prophylaxis, in three it was for oral prophylaxis) and because it apparently was not offered in three. Sixteen were thought to have received one oral dose of VK (1 mg in 11 cases, 0.5 mg in four, not stated in one). Two received two oral doses and two others three oral doses (each 1 mg). Two received a single IM dose: 1 mg in case 27 and 100 μg in case 31.
Four received no VK because parental consent was withheld (in each case the hospital recommendation was for IM prophylaxis; in at least three of the hospitals it was policy to offer oral VK as an alternative). Case 7 had two oral doses (1 mg, days 1+7) whilst breast fed; case 6 “probably” had three oral doses (Konakion Neonatal, 1 mg at birth, 0.5 mg at 1 week and at 1 month); case 3 received 1 mg IM at birth.
In VKDB‐02 the overall incidence of bleeding was significantly less than in the previous studies (RR: 0.27 (95% CI: 0.12 to 0.59), p<0.001) and the incidence among those receiving any oral prophylaxis regimen was lower (RR: 0.24 (95% CI: 0.06 to 1.01), p<0.059).
Four babies in VKDB‐94 and one in VKDB‐02 had received medication other than vitamins before presentation but in none was this considered relevant.
Three first bled within 24 h of birth (“early VKDB”; two received oral VK, the other none) and three between 24 h and 7 days (“classical VKDB”; none received prophylaxis). Twenty six, including all “confirmed” cases suffering ICH, first bled after 7 days of age (“late VKDB”).
There was no case of “early VKDB”. Five had “classical VKDB”, including one with gastrointestinal bleeding on day 2 despite documentation of IM VK 1 mg at birth (see Discussion). Case 6 (“probably” three oral doses of VK) presented at 41 days with a 2‐day history of bruising; non‐accidental injury was considered until abnormal clotting was found and biliary atresia was later diagnosed. Case 7 (two oral doses of VK) bled at 8 weeks and was later found to have cystic fibrosis.8
Presentation was delayed by 1–2 days in six cases. Eight others had “warning bleeds” for 1–7 days (median 2) at one or more sites before presenting with bleeding elsewhere. Warning bleeds included bruising (seven cases), gastrointestinal bleeding (four), oozing from scratches (two), nose bleeds (two) and umbilical oozing (one). Of 10 babies suffering ICH, five had warning bleeds (bruising in three) of 1–4 days' duration.
Two cases presented after delays of 2 days (bruising) and 6 days (nose bleeds and bruising).
Bleeding among those breast fed was significantly less common in VKDB‐02 than in the two earlier studies combined (p<0.01, assuming breast feeding rates of 40–60%).
Liver function was tested in 29 of the 32 cases; in 14 it was normal and in one other probably so. Two had significantly raised gamma glutamyl transferase and alanine transferase but normal bilirubin and are not counted as having liver disease. Twelve had proven liver disease with diagnoses of biliary atresia (four cases), α1 anti‐trypsin deficiency (three), non‐specific hepatitis (two), galactosaemia (one), Alagille syndrome (one) and choledochal cyst (one). In only one baby was liver disease suspected before presentation with bleeding. Eleven of the 12 had serum bilirubin measured within 2 days of presentation; median total bilirubin was 122 μmol/l (range 50–208) and median conjugated bilirubin 84 μmol/l (40–127, n=10); the conjugated fraction represented a median of 64% (38–100%) of the total. Eight of the nine aged >3 weeks would have been clinically jaundiced (bilirubin 70–160 μmol/l).
One had liver disease (biliary atresia) with total bilirubin 118 mol/l and conjugated bilirubin 65 μmol/l, 2 days after presentation with bruising.
Apart from those babies with liver disease and one requiring exchange transfusion for rhesus isoimmunisation, eight had recognised causes for VK deficiency or bleeding. Three bled only at sites of trauma (scalp electrode, circumcision, skin scratch), three failed to thrive before presentation (one subsequently thrived, one was found to have cystic fibrosis and one had probable lipase/co‐lipase deficiency); the ICH in case 4 was associated with a difficult delivery and the gastrointestinal bleeding in case 6 with bowel volvulus.
Two had intestinal bleeding alone: one had campylobacter infection and the other a nasogastric tube. One was found to have cystic fibrosis.8 One bled only after circumcision; he had breastfed poorly and also had hypernatraemic dehydration on presentation with bleeding.
In the two surveys together, six babies first bled within 48 h of birth; in none was a maternal drug implicated (no medication apart from iron and vitamins in 5 cases, and no information for case 1, VKDB‐94).
There are no follow‐up data for 17; all are presumed, from their mode of presentation, to have survived unharmed. Eight were reported to have suffered no sequelae, including three who suffered ICH. Long‐term sequelae were reported in six, all of whom had suffered ICH: two required shunts for hydrocephalus; one had microcephaly, poor vision and hypotonia; one had severe cerebral atrophy and fits; one brain damaged child died from chest infection at 2 years of age; and one was well at 5 years of age with very mild hemiparesis.
No baby died and there were no sequelae from bleeding.
All reported adverse outcomes in the three studies were confined to babies who suffered ICH; details are compared in table 33.
The data for late VKDB in Great Britain and Ireland, reclassified by more exclusive international criteria,5 are presented in table 44.. They confirm a significant reduction in incidence in the latest survey and suggest that the various regimens of multiple‐dose oral prophylaxis currently used do give effective prophylaxis against late bleeding. Overall rates are comparable to those reported from other European countries.5,9
The aim of these studies was to learn more about VKDB, to document the effectiveness of VK prophylaxis and to attempt a conclusion about the most effective regimens considering factors such as reliability of protection, safety and acceptability. We will consider the results of all three studies.
The risk of a breast‐fed or any newborn developing VKDB was significantly lower during the VKDB‐02 survey than previously, for two likely reasons. First, there was a steady decline in the proportion of infants not offered VK prophylaxis: during VKDB‐90 about 14% of all infants were not offered it, in VKDB‐94 about 3% and in VKDB‐02, 0% of breast‐fed infants.6 The incidence of VKDB in babies selected (according to assumed risk) to receive no prophylaxis is estimated to be at least 1 in 10 000.2 Second, there were changes in prophylaxis practice over the period of the three surveys.6 Between VKDB‐90 and VKDB‐94 there was a fall in the use of IM prophylaxis and a corresponding increase in oral prophylaxis, both trends reversing by the time of VKDB‐02. During VKDB‐94 about 60% of babies were routinely offered oral prophylaxis and 25% of these received no doses after day 7, jeopardising protection against late VKDB; by VKDB‐02 IM prophylaxis was recommended to 60% and all but three units using oral VK offered the more effective, multiple‐dose regimens extending to at least 28 days.
Seeking parental consent, either verbal (69%) or written (30%), for VK prophylaxis is now almost universal.6 In VKDB‐94, four of 32 cases had no VK because parents declined it (IM was recommended in one, oral in three). In VKDB‐02, four of seven cases had not received prophylaxis because parents declined it; all were born in units where IM prophylaxis was recommended; protocols in three units suggested oral dosing when IM was refused so presumably this was also declined. In VKDB‐02, refusal was not associated with bleeding in units recommending oral prophylaxis or offering a free choice, so perhaps there is something about the way IM prophylaxis is recommended which invites outright refusal of VK in any form by some parents. This deserves further study; in particular, we would recommend that units sympathetically seek parents' reasons for withholding consent and that those routinely recommending IM prophylaxis review how their alternative oral policy is presented.
Liver disease is known to be a major cause of VK deficiency and of late VKDB. That just one case of VKDB was associated with liver disease during VKDB‐02 suggests that the various prophylaxis regimens most recently documented do protect even babies with liver disease in the study area, but why should oral prophylaxis be more protective now than previously? Use of multiple doses over 28 days or longer, as discussed above, is one likely factor; another is that, with increased vigilance among parents and professionals, congenital liver disease is recognised earlier than it was previously (P McKiernan, personal communication), allowing appropriate additional VK supplementation and so averting bleeding. In the babies with VKDB and (yet undiagnosed) liver disease, the bilirubin levels were unimpressive at the time of presentation; however, all but two were still jaundiced at 3 weeks of age or more (and presumably had persistently dark urine and pale stools, but these details were not requested).
Predisposing factors other than liver disease were individually rare.
We are not alone in reporting VKDB after IM prophylaxis (two cases in VKDB‐94, one in VKDB‐02), but such cases are rare enough that reporting or recording errors must be considered, especially if the bleeding occurs early. The VKDB‐02 case met all the diagnostic criteria, was recorded to have received VK 1 mg IM only 2 days previously and suffered no later bleeding; no explanation has been identified.
Over the period of these studies, the effectiveness of prophylaxis against VKDB has improved considerably and it is notable that in the latest study parents in four of the seven cases had refused the recommended IM prophylaxis, which almost certainly would have protected; regrettably, the reasons for refusal were not sought. In promoting VK prophylaxis for every newborn baby, we must be as sure as possible that we do no harm to the vast majority who would never bleed without it. There must be some risk associated with any IM injection in a baby (especially in any with an undiagnosed bleeding disorder such as haemophilia) and the reported association between IM VK 1 mg prophylaxis and increased risk of childhood leukaemia is not totally refutable. For these reasons, we remain interested in the possibility of parents giving daily or weekly oral VK drops as a more physiological and acceptable means of routine prophylaxis, as used effectively in some other European countries,5,9 whilst reserving IM prophylaxis for the minority at highest risk of developing VKDB.
In the UK, Konakion Neonatal (Roche) has now been withdrawn by the manufacturer, in line with its policy for the whole of Europe. The more costly and relatively untried micellar preparation, Konakion MM, must now be used for IM prophylaxis for all high risk babies and for standard risk babies born in units lacking confidence in oral prophylaxis. Monitoring of VKDB has been resumed to document any consequences of the enforced changes in prophylaxis.
We thank the UK Department of Health for funding the studies, the BPSU for making them possible and all reporting paediatricians for their collaboration and forbearance. We also thank Drs Martin Shearer and Paul Clarke, referees, for very constructive criticism.
The authors wish to pay tribute to the late Professor Dr Anton Sutor, colleague and friend, who did so much to promote understanding of all aspects of vitamin K deficiency bleeding.
BPSU - British Paediatric Surveillance Unit
ICH - intracranial haemorrhage
IM - intramuscular
VK - vitamin K
VKDB - vitamin K deficiency bleeding
Competing interests: JHT and AWM have previously received funding from Roche Pharmaceuticals. JHT has acted as an expert witness to the MHCA in an appeal for approval of an oral preparation of vitamin K1 by another company.